Intercept Pharmaceuticals Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Intercept (ICPT) Shares Likely to Keep Moving Higher, Says RBC
May 11, 2015 3:53 PM EDTRBC Capital reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) with a price target of $490. Comments follow the company's Q1 results and comments from management. Analyst Michael J. Yee thinks catalysts will keep shares moving higher.
"We reiterate our Outperform and see catalysts ahead that are likely to keep stock moving higher: (1) we continue to... More
Intercept (ICPT) FV Target Lifted to $363 at Janney Capital; 'Enjoying this Ride'
May 11, 2015 1:30 PM EDTJanney Capital analyst Chiara Russo bumped her fair value target on Buy-rated Intercept Pharmaceuticals (NASDAQ: ICPT) to $363.00 (from $350.00) following in-line Q1 results.
Russo commented, "1Q15 could have gone differently for ICPT. Instead, everything went very right. OCA for NASH officially received... More
Intercept's (ICPT) Rolling NDA, MAA Submissions for OCA Appear on Track; Needham & Company Affirms at 'Buy'
May 11, 2015 12:47 PM EDTNeedham & Company affirms Intercept Pharma (NASDAQ: ICPT) with a Buy rating and $500 price target following Q1 results issued Monday morning.
Ahead of the opening bell, Intercept reported Q1 EPS of ($1.78) and revenue of $405,000, versus the analyst EPS estimate of ($1.69) and revenue of $1.7... More
Intercept Pharma (ICPT) Misses Q1 EPS by 9c
May 11, 2015 6:25 AM EDTIntercept Pharma (NASDAQ: ICPT) reported Q1 EPS of ($1.78), $0.09 worse than the analyst estimate of ($1.69). Revenue for the quarter came in at $405 thousand versus the consensus estimate of $1.7 million.
Net loss for the first quarter of 2015 included non-cash expenses totaling $10.9 million including $9.7 million of stock-based... More
